MindWalk Holdings Corp. Common Stock (HYFT) Stock Price

HYFTStock

$1.42−56.88%52W

Market Cap$66.72M

P/E—

PEG Ratio—

Div yield—

Beta0.79

HYFT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-16.07%

Price vs S&P 500 (4W)-1.58%

VGM Score30.94

Book Value / Share (Quarterly)$0.18

P/TBV (Annual)6.60x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-9.03%

Cash Flow / Share (Quarterly)$-0.20

Price vs S&P 500 (YTD)-36.13%

Gross Margin (TTM)58.80%

Net Profit Margin (TTM)-89.66%

EPS (TTM)$-0.22

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-0.22

Revenue Growth (5Y)-2.78%

EPS (Annual)$-0.22

ROI (Annual)-91.32%

Gross Margin (Annual)58.80%

Net Profit Margin (5Y Avg)-107.73%

Cash / Share (Quarterly)$0.18

Revenue Growth QoQ (YoY)-41.05%

ROA (Last FY)-65.26%

Revenue Growth TTM (YoY)-36.55%

EBITD / Share (TTM)$-0.23

ROE (5Y Avg)-78.99%

Operating Margin (TTM)-96.01%

Cash Flow / Share (Annual)$-0.20

P/B Ratio7.89x

P/B Ratio (Quarterly)6.60x

Net Income / Employee (Annual)$-98,847

EV / Revenue (TTM)5.45x

Net Interest Coverage (TTM)-112.52x

ROA (TTM)-50.17%

EPS Incl Extra (Annual)$-0.22

Current Ratio (Annual)2.80x

Quick Ratio (Quarterly)2.58x

3-Month Avg Trading Volume0.30M

52-Week Price Return-56.88%

Revenue / Employee (TTM)$110,191

Tangible BV / Share (Quarterly)$0.18

P/S Ratio (Annual)5.96x

Asset Turnover (Annual)0.73x

52-Week High$2.35

Operating Margin (5Y Avg)-118.61%

EPS Excl Extra (Annual)$-0.22

CapEx CAGR (5Y)-21.96%

26-Week Price Return-4.83%

Quick Ratio (Annual)2.58x

13-Week Price Return-10.39%

Total Debt / Equity (Annual)0.30x

Current Ratio (Quarterly)2.80x

Enterprise Value$61.32M

Revenue / Share Growth (5Y)-20.96%

Asset Turnover (TTM)0.56x

Revenue / Employee (Annual)$110,191

Inventory Turnover (Annual)4.96x

Pretax Margin (Annual)-99.96%

Cash / Share (Annual)$0.18

3-Month Return Std Dev86.85%

Gross Margin (5Y Avg)48.80%

Net Income / Employee (TTM)$-98,847

ROE (Last FY)-118.72%

Net Interest Coverage (Annual)-35.10x

EPS Basic Excl Extra (Annual)$-0.22

P/FCF (TTM)104.08x

Receivables Turnover (TTM)4.00x

Total Debt / Equity (Quarterly)0.30x

EPS Incl Extra (TTM)$-0.22

Receivables Turnover (Annual)4.00x

ROI (TTM)-70.22%

P/S Ratio (TTM)5.96x

Pretax Margin (5Y Avg)-117.33%

Revenue / Share (Annual)$0.24

Tangible BV / Share (Annual)$0.18

Price vs S&P 500 (52W)-75.19%

Year-to-Date Return-24.18%

5-Day Price Return3.76%

EPS Normalized (Annual)$-0.22

ROA (5Y Avg)-46.11%

Net Profit Margin (Annual)-89.66%

Month-to-Date Return6.98%

EBITD / Share (Annual)$-0.24

Operating Margin (Annual)-99.29%

LT Debt / Equity (Annual)0.03x

ROI (5Y Avg)-58.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.22

P/TBV (Quarterly)6.60x

P/B Ratio (Annual)6.60x

Inventory Turnover (TTM)4.96x

Pretax Margin (TTM)-99.97%

Book Value / Share (Annual)$0.18

Price vs S&P 500 (13W)-13.18%

Beta0.79x

Revenue / Share (TTM)$0.24

ROE (TTM)-85.76%

52-Week Low$0.72

vGradeD

gGradeD

mGradeD

vgmGradeD

HYFT Earnings Surprise History

Q1 25-0.03est. -0.03

Q2 25-0.04est. -0.03

Q3 25-0.04est. -0.01

Q4 25-0.04est. -0.03

Q1 26-0.04est. -0.04

HYFT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
HYFTMindWalk Holdings Corp. Common Stock	D	D	D	$1.42
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About MindWalk Holdings Corp. Common Stock

MindWalk Holdings Corp is a bio-native AI company that accelerates drug discovery and development using proprietary HYFT technology and its LensAI platform. The company integrates molecular sequence, structure, function, and literature data into a unified computational framework, paired with an internal wet lab for validation. This integrated approach enables rapid applications in epitope mapping, protein design, vaccine exploration, and large-scale biologics analysis, helping to advance drug candidates faster from discovery to validation.